Detalles de la búsqueda
1.
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Blood
; 119(20): 4608-13, 2012 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-22451423
2.
A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2.
EClinicalMedicine
; 66: 102317, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-38192592
3.
Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416.
Clin Cancer Res
; 11(21): 7938-44, 2005 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16278419
4.
A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.
Cancer Res
; 62(12): 3408-16, 2002 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-12067983
5.
Successful management of life-threatening hemorrhage in a patient with synchronous lupus anticoagulant and factor VIII inhibitor.
J Vasc Surg
; 36(4): 853-5, 2002 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-12368750
Resultados
1 -
5
de 5
1
Próxima >
>>